From 17 March 2017 through 22 May 2020, pralsetinetib was given to 92 patients with RET fusion-positive NSCLC, and 29 patients who had never received treatment were given the drug by 11 July 2019. This evidence concerns the gene RET and non-small cell lung carcinoma.